Allogene Therapeutics, Inc. Profile Avatar - Palmy Investing

Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimer…

Biotechnology
US, South San Francisco [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of ALLO's Analysis
CIK: 1737287 CUSIP: 019770106 ISIN: US0197701065 LEI: - UEI: -
Secondary Listings
ALLO has no secondary listings inside our databases.